Skip to content

Comparison of the effectiveness of ascorbic acid and omega-3 on the incidence of atrial fibrillation and hospitalization

Comparison of the effectiveness of ascorbic acid and omega-3 on the incidence of atrial fibrillation and hospitalization after coronary artery bypass graft surgery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171114037462N1
Enrollment
50
Registered
2020-04-14
Start date
2018-09-17
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Atrial Fibrillation. Condition 2: Coronary Artery Bypass Graft Surgery. Atrial fibrillation and flutter

Interventions

Intervention 1: Intervention group1:Intervention group1 :In addition to 2.5 mg Bisoprolol (Merck Company), two 1000 mg Omega3 capsules prescribed at least 24 hours before operation and daily afterwa

Sponsors

Karaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The Patient must have undergone Coronary artery bypass graft surgery Before surgery, the patient's ECG's rhythm should be sinusoidal Preoperative oral beta-blocker administration to the patient Informed consent

Exclusion criteria

Exclusion criteria: Using of vitamin supplements containing antioxidants or omega-3 supplements in the last 3 days History of atrial fibrillation History of congenital heart disease History of severe valvular disease Sensitization to omega-3 or vitamin C, which is a severe GI complications Permanent or temporary pacemaker Ejection fraction less than 40% Severe respiratory disease ,COPD , pneumonia Severe hepatic disease ,cirrhosis , fulminant hepatitis atrioventricular block or bradycardia less than 50 beats per minute End stages renal disease Taking class 1 and 3 antiarrhythmic drugs or digoxin

Design outcomes

Primary

MeasureTime frame
Atrial fibrilation. Timepoint: During Hospitalization using ICU monitoring. Method of measurement: ECG.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Bayat

Karaj University of Medical Sciences

rajaei@abzums.ac.ir+98 26 3457 0030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026